How to Optimize Cholesterol Management in High-Risk CV Patients
Agenda
AHA/ACC Guidelines on the Management of Blood Cholesterol
AHA/ACC Guideline: Lifestyle Modification for ASCVD Risk Reduction
Secondary Prevention in Patients Not at High ASCVD Risk
Secondary Prevention in Patients at Very High ASCVD Risk
FOURIER: Cumulative Incidence of CV Events
AHA/ACC Guidelines Primary Prevention of ASCVD
Cost-Effectiveness of PCSK9 Inhibitors
EAS/ESC Consensus Statement: Dyslipidemia in Very High-Risk Patients
Stepwise, Incremental Therapeutic Strategy for Lipid Reduction in High-Risk Patients
Second STEMI and Residual Risk
Myocardial Infarction and Life Expectancy by Sex and Ethnicity
7-Year Risk of a Second MI Among 30-Day Survivors of First MI
Patient Case
Controlling Modifiable Risk Factors Is Essential in High-Risk ACS Patients
Addressing Residual Risk: Every MI Patient Should Be On a Statin (and Possibly Ezetimibe As Well)
FOURIER: Cumulative Incidence of Cardiovascular Events
Fourier: Results of an Exploratory Analysis in Patients with LDL-C <0.26 mM at Week 4
Safety Data From 5 Alirocumab Trials: No Safety Signal for Very Low LDL-C Levels
AHA Guidelines for Secondary ASCVD Prevention: Use of PCSK9 Inhibitors
Case Study in Secondary Prevention in a Patient With PAD, CAD, or Polyarterial Disease
Case Presentation: Patient Characteristics
How Should Therapy Be Advanced for This Patient?
Presence of Residual CV Risk in Large Prospective Studies of Optimal Statin Therapy
The TIMI Risk Score for Secondary Prevention
What Types of Events Is This Patient at Risk For?
How Should the Patient With Multiple Risk Factors Be Managed?
FOURIER: Cumulative Incidence of CV Events
Older Patients and Optimal LDL-C Reduction Therapy
Are There LDL-C Levels That Are Too Low?
Summary
Real Life Data With PCSK9 Inhibitors
Introduction/Overview
Majority of Very High-Risk Patients Not at LDL-C Level Target, < 70 mg/dL
EAS/ESC Consensus Statement: Dyslipidemia in Very High-Risk Patients
LDL-C Reduction With PCSK9 Inhibitors: Real-World Data From a Regional Lipid Clinic
LDL-C Reduction From Baseline With PCSK9 Inhibitors at Various Doses
Observational Cohort Study: CV History at Baseline (N = 1186)
Median (Q1, Q3) LDL-C Reduction Following Evolocumab Initiation
Adverse Drug Reactions: Observational Cohort Study
Summary and Conclusions
Abbreviations
Abbreviations (cont)
Abbreviations (cont)